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Popular science summary 
Our intestinal tract works hard for us continuously, it helps us take up important 
nutrients, vitamins and minerals from the food we ingest. Some of these processes 
take place with the help of an estimated amount of 1014  "good" microorganisms such 
as bacteria that ferment fiber. The immune system that is present in the intestinal wall 
has the complex task to distinguish between the beneficial food derived molecules 
and "good" microorganism and detrimental pathogens. Failure to maintain this 
balancing act, known as homeostasis, in combination with environmental factors and 
genetic predisposition can lead to chronic inflammatory bowel disease (IBD) such as 
Crohn's disease and Ulcerative colitis. Moreover, patients with IBD may develop 
inflammation induced colorectal cancer (CRC) when they have a genetic 
predisposition or when IBD treatment fails. 
 
Classical dendritic cells (cDCs) are an important part of the intestinal immune system. 
cDCs are specialized 'sensors' that can recognize patterns and molecules (known as 
antigens) that are derived from pathogenic bacteria, good bacteria, the body's own 
cells and food with the help of a broad spectrum of different receptors that these cDCs 
express. Upon recognition of antigens the dendritic cells can activate specialized T 
cells that can either help clear detrimental pathogens/ tumor cells or prevent an 
immune response towards beneficial bacteria/ food derived molecules. In the intestine 
2 main types of cDCs are present: cDC1 and cDC2. cDC1s are important in activating 
T helper 1 (Th1) cells that produce IFNγ which are important in the defense against 
parasitic and intracellular infections and in parts of the intestine they can induce 
regulatory T cells that possibly reduce responses to our own cells and food derived 
antigens. In other parts of the body cDC1s have been shown to activate Th1 cells and 
cytotoxic T cells with anti-tumor properties. cDC2 cells play a role in activating T 
helper 17 (Th17) cells and T helper 2 (Th2) cells, the former have different roles in 
maintaining homeostasis in the intestine while the latter are important for the defense 
against parasitic infections. To date however the role that cDC1s and cDC2s have in 
intestinal inflammation and CRC remains to be elucidated.  
 
In the current thesis I assessed the role of cDC2s in an experimental model of T cell 
induced colitis and the role of cDC1s in an experimental model of inflammation 
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induced CRC. T cell induced colitis is thought to be dependent on a subset of pro-
inflammatory Th17 cells. In manuscript I we showed that cDC2 cells play a role in 
the initiation phase of colitis development but were redundant once disease 
progressed. We suspect that the inflammatory environment attracts another type of 
inflammatory dendritic cells that is capable of inducing and maintaining pro-
inflammatory T cells. Manuscript II describes that cDC1 cells have no significant role 
in inducing an anti-tumor response in a mouse model of inflammation induced CRC 
In the absence of cDC1 cells, despite a reduction in Th1 cells, mice developed tumors 
similar to mice that had normal amounts of cDC1 cells. 
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Dansk resumé 
Vores fordøjelseskanal arbejder hele tiden hårdt for os, den hjælper os med at optage 
vigtige nærringsstoffer, vitaminer og mineraler fra den mad vi indtager. Nogle af 
disse processer finder sted ved hjælp af en estimeret mængde på 1014 ”gode” 
mikroorganismer, som fx bakterier der fermenterer fibre. Immunsystemet som er til 
stede i tarmvæggen har den komplekse opgave at se forskel mellem de gavnlige 
molekyler fra fødevarer, samt ”gode” mikroorganismer og skadelige pathogene 
organismer. Fejller denne balancegang, kendt som homeostasis, i sammenhæng med 
miljøfaktorer og genetisk prædisposition kan dette føre til inflammatorisk tarm 
sygdom (IBD) så som Crohn’s sygdom og ulcerativ colitis. Hertil kommer at patienter 
med IBD kan udvikle inflammationsinduceret colorektalcancer (CRC) når de har en 
genetisk prædisposition eller når IBD behandlingen fejler. 
 
Klassiske dendritceller (cDCs) er en vigtig del af tarmens immunforsvar. cDCs er 
specialiserede ”sensorer”, som kan genkende mønstre og molekyler, der kommer fra 
pathogene bakterier, gode bakterier, kroppens egne celler og fødevarer (kendt som 
antigener), ved hjælp af et bredt spekter af forskellige receptorer som cDCs udtrykker. 
Ved antigengenkendelse kan dendritceller aktivere specialiserede T celler, som enten 
kan hjælpe med at fjerne pathogener/tumor celler, eller forhindre et immunrespons 
mod nyttige bakterier/molekyler fra mad. I tarmen findes to hovedtyper af cDCs: 
cDC1 og cDC2. cDC1 er vigtige i aktiveringen af T hjælper 1 celler, der producerer 
IFNγ, som er vigtig i forsvaret mod parasitter og intracellulære infektioner, og i dele 
af tarmen kan de inducere regulatoriske T celler, der formentlig reducerer responsen 
imod vores egne celler samt antigener fra fødevare. I andre dele af kroppen er det 
blevet vist at cDC1 kan aktiverer T hjælper 1 celler og cytotoksiske T celler med anti-
tumor egenskaber. cDC2 celler spiller en rolle i aktiveringen af T hjælper 17 celler og 
T hjælper 2 celler, hvor de første har forskellige roller i vedligeholdelsen af 
homeostasis i tarmen, mens de andre er vigtige i forsvaret imod parasitinfektioner. Til 
dato er rollen som cDC1 og cDC2 spiller i tarminflammation og CRC dog stadig ikke 
klarlagt.       
 
I denne afhandling vurderer jeg cDC2 rolle i en eksperimentel model af T celle-
induceret colitis og cDC1 rolle i en eksperimentel model for inflammations-induceret 
 8 
CRC. T celle induceret colitis menes at være afhængig af en subpopulation af 
inflammatoriske T hjælper 17 celler. I manuskript I viste vi at cDC2 celler spiller en 
rolle i initieringsfasen af colitisudvikling, men var overflødige i den udviklede 
sygdom. Vi mistænker at det inflammatoriske miljø tiltrækker andre typer af 
inflammatoriske dendrit celler, som er i stand til at inducere og vedligeholde 
proinflammatoriske T celler. Manuscript II beskriver at cDC1 celler ikke spiller 
nogen signifikant rolle i induceringen af anti-tumor responsen i en musemodel af 
inflammationsinduceret CRC. I fraværet af cDC1 celler, selvom der er en reduktion i 
T hjælper 1 celler, udvikler mus tumorer sammenligneligt med mus der har normale 
mængder af cDC1 celler.   	
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Abbreviations 
IBD inflammatory bowel disease 
CRC colorectal cancer 
cDC classical dendritic cell 
Th T helper 
LP lamina propria 
GALT gut associated lymphoid tissue 
RegIIIy regeneration islet-derived protein IIIy 
TLR toll like receptor 
IL interleukin 
NOD2 nucleotide-binding oligomerization domain 
IEC intestinal epithelial cell 
PRR pattern recognition receptor 
MAMP microbe associated molecular pattern 
DAMP damage associated molecular pattern 
LPS lipopolysaccharide 
NLR NOD-like receptor 
ENS enteric nervous system 
ILC innate lymphoid cell 
NK natural killer  
Lti lymphoid tissue-inducer 
MLN mesenteric lymph node 
PP peyer's patch 
SILT solitary isolated lymphoid tissue 
FAE Follicle associated epithelium 
SED subepithelial dome 
GAP goblet cell associated passage 
MHC major histocompatibility complex 
TCR T cell receptor 
MadCAM1 vascular addressin cell adhesion molecule 1 
RA retinoic acid 
CPR15 G-coupled receptor 15 
CTL cytotoxic T lymphocyte 
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STAT signal transducer of activated T cells 
ROR retinoic acid receptor related orphan receptor 
Treg T regulatory cell 
FoxP3 forkhead box protein 3 
CSN conserved non-coding DNA sequence 
IEL intraepithelial lymphocyte 
HSC hematopoietic stem cell 
BM bone marrow 
MDP macrophage dendritic cell progenitor 
M-CSFR macrophage colony stimulating factor receptor 
Flt3 fms-like tyrosine kinase 3 
CDP common DC progenitor 
SIRPα signal regulatory protein α  
XCR1 chemokine XC receptor 1 
GM-CSF granulocyte-macrophage colony-stimulating factor 
Id2 DNA-binding protein inhibitor-2 
IRF8 interferon regulatory factor 8 
BATF3 basic leucine zipper ATF-like transcription factor 3 
KLF4 kruppel like factor 4 
Notch2 receptor neurogenic locus notch homolog protein 2 
CD crohn's disease 
UC ulcerative colitis 
GWAS genome-wide association studies 
AOM azoxymethane 
DSS dextran sulfate sodium  
TNBS trinitobenzene solphonic acid 
Scid severe combined immune deficient 
MDP muramyl dipeptide 
DEC-205 endocytotic c-type lectin receptor 205 
Smad7 SMAD family member 7 
CAC colitis associated colorectal cancer 
ROS reactive oxygen species 
APC adenomatous polyposis coli 
COX-2 cyclooxygenase-2 
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IDO indoleamine 2,3-dioxygenase 
5-ASA 5-aminosalicylate 
NSAID non-steroid anti-inflammatory drugs 
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Chapter 1 Intestinal biology and immunity 	
1.1 The intestinal tract 
The intestine is anatomically adapted to digest food and absorb nutrients, minerals 
and water. Starting with the stomach and ending at the anus, the intestine forms a 
continuous tube that is lined with a single layer of epithelial cells. The intestinal tract 
can be roughly divided in the small intestine and the large intestine, which are 
separated by the ceacum. The small intestine and the large intestine have marked 
structural differences primarily dictated by the their physiological functions. The 
surface of the small intestine is covered by finger-like projections called villi, which 
are covered by a “brush border” consisting of a multitude of membrane projections 
known as microvilli, which serve to increase the surface area for optimal digestion 
and nutrient uptake. In contrast, the surface of the colon is relatively flat, but harbors 
a larger community of commensal microbiota compared to the small intestine. These 
microbes play an essential role for our health, through for example the fermentation 
of fiber, and the production of important essential vitamins and metabolites. As will 
later be described, they are also required for the function and development of the 
immune system.  
 
The intestinal wall is build up of several distinct layers; in closest contact with the 
lumen is the mucosa, followed by the submucosa, the muscularis mucosa (a thin 
muscle layer) and the outer serosa (fibrous tissue separating the intestine from the 
peritoneal cavity). The mucosa comprises of the lamina propria (LP) and the 
muscularis mucosa, and is covered by the single layered epithelium that forms a 
barrier between the intestinal lumen and the underlying tissue. The LP is made up of 
loosely packed connective tissue that contains the large majority of innate and 
adaptive immune cells in the intestine, although immune cells can also be found in the 
intestinal epithelium and serosa. The main immune effector sites of the intestine are 
the LP and the epithelium, whereas induction of immune responses primarily takes 
place in draining lymph nodes and gut associated lymphoid tissue (GALT). In this 
thesis work the main focus will be on examining the immune response in the colon LP 
and intestinal draining lymph nodes.  
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1.2 The challenges for the intestinal immune system 
The total area of the intestinal surface is estimated to be 32m2 making it the body's 
largest surface area that is in contact with the outside environment [1]. The immune 
system of the intestine is continuously exposed to dietary and bacterial derived 
products and therefore faces unique challenges compared to other organs. The major 
function of the intestine is to take up nutrients from food (e.g. proteins, vitamins, 
lipids and carbohydrates) and in this process it is important that the immune system 
doesn’t overreact to dietary protein antigens. Digestion of plant polysaccharides and 
certain other dietary substances is to some extent dependent on commensal microbiota 
that are found throughout the intestinal tract at an estimated total count of 1014; these 
bugs also need to be tolerated [2, 3]. The mucosal surface has both physical and 
biological barrier functions in place to help prevent breaching of this layer by 
pathogens or the microbiota. Further, there is a continuous cross-talk between the 
immune system and the microbiota as well as between immune- and non-
hematopoietic cells in the mucosa that are key to maintaining tissue homeostasis. The 
intestinal immune system comprises of a diverse population of innate and adaptive 
immune cells with differential functions that cooperate tightly to elicit appropriate 
immune responses. Moreover, immune cells within the intestine, including 
macrophages and dendritic cells are environmentally imprinted with unique properties 
that serve to help maintain tissue homeostasis. In the intestine appropriate responses 
broadly comprise: recognition, containment and elimination of pathogens and 
tolerance towards beneficial microbiota and food antigens. Breakdown of the balance 
between these distinct tasks can lead to chronic infections, inflammatory bowel 
disorders or food intolerances. Moreover, the rapid and continual renewal of the 
intestinal epithelium (with an estimated half life of 4-5 days), likely in combination 
with continual immune activation makes that especially the large intestine is at high 
risk of developing malignancies, often as a result of chronic inflammatory disorders 
[4-6]. In the following chapters I will give a broad overview of the mucosal barrier, 
the intestinal immune system and its sub-compartments. 
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1.3 The epithelial barrier 
In addition to enterocytes that are specialized in nutrient uptake, the intestinal 
epithelium contains specialized secretory epithelial cells, including goblet cells, 
paneth cells and tuft cells that have diverse antimicrobial properties. Goblet cells 
secrete mucin glycoproteins, which form a mucus layer that covers the epithelial 
surface. In the human small intestine goblet cells comprise about 10% of all epithelial 
cells, this proportion gradually increases to about 25% or less in the distal colonic 
epithelium [3]. The colon has two structurally distinct mucus layers, a loose outer 
mucus layer that contains large numbers of commensal bacteria that utilize the mucus 
as an energy source, and an epithelium-attached inner layer that is denser and contains 
few bacteria [7]. The small intestinal epithelium, in contrast, is covered with a single 
mucus layer that is looser, but contains antimicrobial peptides such as defensins and 
regeneration islet-derived protein IIIy (RegIIIy) [8].  These antimicrobial peptides are 
produced by paneth cells, which are long-lived columnar epithelial cells that in 
contrast to other epithelial cells move down to the base of the crypts after 
differentiating from stem cells [8, 9]. Paneth cells are unique to the small intestinal 
epithelium and release antimicrobial peptides in response to interleukin-22 (IL-22), 
stimulation of Toll-like receptors (TLRs), nucleotide-binding oligomerization domain 
2 (NOD2) or cholinergic nerves [4, 8, 9]. Lastly, tuft cells constitute only about 0.4% 
of the intestinal epithelium and are less well characterized, mainly by the lack of 
suitable identifying markers [10]. These cells have a "tuft" of microvilli extending 
into the lumen, sense the environment through taste chemosensory receptors and 
transduce sensory signals, similar to taste receptors that respond to bitter-, sweet-, and 
umami-tasting substance, via Trpm5 [11]. Although their function is largely 
unknown, they have recently been implicated in the sensing of protozoa and helminth 
infections to which they respond with production of IL-25 which in turn activates type 
2 immunity [12, 13].  
Intestinal epithelial cell (IEC) function depends on a continuous cross-talk between 
commensal microbiota and the epithelium. This cross-talk is largely regulated by 
pattern recognition receptors (PRRs) that recognize microbe associated molecular 
patterns (MAMPs) and molecular patterns associated with cell damage or death 
known as damage associated molecular patterns (DAMPs). MAMPs include 
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lipopolysaccharide (LPS), bacterial lipoproteins and lipoteichoic acids, flagellin, 
unmethylated CpG DNA of bacteria and viruses, double stranded RNA and single-
stranded viral RNA [14]. DAMPs are endogenous molecules that are released upon 
cell damage that can consist of extracellular matrix components, intracellular 
mitochondrial or nucleus components or components that are released during 
autophagy [15]. Each PRR has specificity for a given DAMP or MAMP, but different 
cell populations based on the location and functionality of the cell can express them in 
various combinations.  PRRs such as Toll like receptors (TLRs) and NOD-like 
receptors (NLRs) are selectively expressed in distinct IEC compartments, a 
mechanism that is thought to partially contribute to the intestinal immune systems 
ability to discriminate between commensal and pathogenic bacteria. TLR5 for 
example is expressed at the basolateral surfaces of IECs, while TLR 3, 7, 8 and 9 are 
expressed in intracellular endosomal organelles and NLRs are present in the 
cytoplasm of IECs [16]. With this strategic placement of PRRs IECs only recognize 
pathogenic bacteria that actively invade the epithelial barrier [17]. As such IECs can 
act as early sentinels that upon activation can secrete mediators such as cytokines and 
chemokines that act to recruit and activate innate immune cells in the underlying LP 
tissue [18, 19]. Moreover, tight-junction integrity and trans-epithelial permeability are 
regulated by commensal microbial signals, including Toll like receptor 2 (TLR2) 
dependent redistribution of tight-junction proteins to apical cell-cell contacts [20]. 
Finally, like paneth cells, enterocytes are capable of producing antimicrobial peptides 
such as RegIIIy throughout the colon and small intestine [19]. Although the 
mechanisms are not completely understood, the regional differences in antimicrobial 
peptide production throughout the intestine is thought to influence the composition 
and localization of microbial communities [19]. 
Thus, the epithelial barrier is a network of specialized epithelial cells that collectively 
help to maintain barrier integrity and the beneficial microbiota but also serve to limit 
access of microbes to the underlying LP. 
1.4 Innate immune cells in the intestinal lamina propria 
The intestinal LP contains a large population of innate and adaptive immune cells that 
help maintain intestinal barrier integrity and serve important functions in immune 
surveillance. Innate immune cells act as sentinels and respond rapidly, within minutes 
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to hours, to challenge when needed. The innate immune system consists of leukocytes 
that include populations of monocytes, macrophages, granulocytes, innate lymphoid 
cells and dendritic cells (DC).  
 
Mononuclear phagocytes (macrophages and DCs) have been most implicated in the 
uptake and presentation of antigen in the intestine. While the main function of DCs is 
antigen presentation (which will be described in more detail in chapter 3), intestinal 
macrophages are at least in steady state a non-migratory population and thus their 
antigen presenting function maybe limited to the presentation of antigen to adaptive 
immune cells within the LP. Intestinal macrophages serve important phagocytic roles 
including the degradation of microorganisms and dead cells and production of 
mediators that regulate epithelial function and local immunity. Intestinal macrophages 
are well adapted to the microbe rich environment they occupy. They are highly 
bactericidal and can engulf bacteria through phagocytosis, but in contrast to 
macrophages in other tissues intestinal macrophages don't produce pro-inflammatory 
mediators in response to ingestion of bacteria [21]. Instead they produce IL-10, which 
serves to prevent inflammation and promotes survival and expansion of FoxP3+ 
regulatory T cells in the mucosa [22-24]. Intestinal macrophages lack activating 
receptors (e.g. FcαR, FcγR, FcγRIII and some complement receptors), and although 
they express some PRRs (i.e. TLRs and NLRs) they are less responsive to stimulation 
of these receptors [21, 25]. They instead express inhibitory receptors like IL-10R and 
receptors for TGFβ. IL-10 has been implicated in the regulation of the PRR 
unresponsiveness while TGF-β derived from intestinal stroma has been suggested to 
drive the regulatory state of intestinal resident macrophages [26-29]. IL-10R on 
macrophages is essential for intestinal homeostasis as mice lacking IL-10R on 
macrophages develop spontaneous colitis [30, 31]. Moreover tissue resident 
macrophages produce IL1β, which has been implicated in the maintenance of stable 
Th17 activity in the steady state [32].  
 
Eosinophils and mast cells are part of a larger group of granulocytes that are 
characterized by the presence of granules in their cytoplasm. These cells are mostly 
associated with allergic responses and responses to parasitic worms. However, recent 
studies suggest that some of these granulocytes have more diverse functions in 
maintaining intestinal homeostasis. For example eosinophils, which are found 
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throughout the intestinal LP in steady state have been implicated in tissue repair in 
steady state and during intestinal inflammation [33, 34]. More recently eosinophils 
have been implicated, through the production of APRIL and IL-1β, in T-cell 
independent IgA class switching [35, 36]. Mast cells are also found throughout the 
healthy gastrointestinal tract where they produce mediators (e.g. histamine and 
tryptase) that regulate epithelial barrier integrity [37]. Histamine affects the function 
of blood vessels, smooth muscle contraction and mucus production by epithelial cells 
[37]. Mast cells also interact with the local enteric nervous system (ENS) through 
production of histamine, proteases and lipid mediators by which they communicate to 
the ENS for the stimulation of peristalsis for rapid expulsion of for example toxins or 
helminthes [38]. It is however not known if mast cells control peristalsis under 
homeostatic conditions [37]. Mast cells also express TLRs and are thus likely to have 
a role in host defense against microbes [37].  
 
Innate lymphoid cells (ILCs) are a recently described innate immune cell type that is 
present in mucosal tissues. ILCs develop from common lymphoid precursors, and can 
be subdivided into ILC1, ILC2 and ILC3 cells, with an effector cytokine-profile and 
transcription factor-dependence largely analogous to Th1, Th2 and Th17 cells, 
respectively. In contrast to adaptive lymphoid cells, ILCs do not express an antigen 
receptor. Instead, they are thought to rapidly respond to cytokines produced in the 
tissue environment. Group 1 ILCs are characterized by their Th1 like-phenotype and 
consist of natural killer (NK) cells and ILC1s. While NK cells display cytotoxic 
activities they can also produce large quantities of IFNγ in response to IL-12 similar 
to ILC1s [39-41]. Group 1 ILCs are implicated in the protection against bacteria and 
intracellular pathogens such as Salmonella enterica [42, 43]. Croup 2 ILCs are 
characterized by their expression of GATA3 and production of Th2 associated 
cytokines [39, 41]. Group 2 ILCs play an important role in resistance to nematodes 
such as Nippostrongylus brasiliensis and control of eosinophil homeostasis [44-46]. 
They produce Th2 cytokines (e.g. IL-4, IL-5, IL-13) in response to IL-25 and IL-33 
[41]. Lastly, group 3 ILCs arise from lymphoid tissue-inducer (LTi) like precursors 
that require RORγt for their development [47]. Group 3 ILCs can be found as IL-22 
producing or IL-17 producing subsets, the first expresses NKp46 and is found 
primarily in the small intestine and the latter is found in higher numbers in the colon 
[48]. RORγt+ ILC3s are important in early defense against intestinal pathogens such 
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as Citrobacter rodentium [49, 50] and in resistance to epithelial injury and intestinal 
inflammation [51]. In more recent studies a subset of group 2 and 3 ILCs have been 
shown to express MHCII, which possibly expands the functional properties of ILCs to 
that of antigen presenting cells [52-54]. MHCII+ ILC2s and T cell cross-talk 
contributed to their mutual expansion and cytokine production, this interaction was 
crucial for a type 2 immune response towards Nippostrongylus brasiliensis [54]. 
Moreover, RORγt+MHCII+ ILC3s have been proposed to induce apoptosis of 
activated T cells specific for commensal microbiota [52, 53]. This may be an 
additional mechanism by which the immune system maintains homeostasis and 
controls immune responses towards commensal microbiota. 
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Chapter 2 Intestinal immune activation compartments and 
adaptive immunity 	
Adaptive immune responses are initiated in inductive sites of the intestinal immune 
system while B and T cells perform their effector functions in so called effector sites. 
These inductive sites are organized lymphoid structures with B and T cell areas 
encapsulated in organized stromal tissue. Inductive sites include the gut draining 
mesenteric lymph nodes (MLN) and gut associated lymphoid tissue (GALT) 
consisting of Peyer’s patches (PP) in the small intestine and ceacal and colonic 
patches in the large intestine, whereas solitary isolated lymphoid tissues (SILT) can 
be found throughout the intestine. While the MLN are typical lymph node structures, 
connected to the intestinal mucosa via afferent lymphatic vessels, GALT are 
lymphoid structures localized directly underneath the epithelium in the intestine. 
MLN and PP develop prenatally and contain distinct B and T cell areas. In contrast, 
SILT consists primarily of B cell follicles and develops after birth in response to 
dietary and microbial factors [55, 56]. Effector sites include the intestinal epithelium 
and LP, where lymphocytes primed at inductive sites carry out their function.  
 
2.1 Routes and mechanisms of antigen uptake by dendritic cells 
The proposed mechanisms by which DCs acquire luminal antigens are many, and 
depend on the site of antigen acquisition and type of antigen. GALT structures are 
covered by a specialized epithelium, the follicle associated epithelium (FAE) that 
contains microfold cells (M cells). M cells are of epithelial origin and act as the port 
of entry for particulate luminal antigens such as bacteria. Luminal contents are 
endocytosed and transported by endocytic vesicles within M cells to the subepithelial 
dome (SED), where they are transferred to underlying DCs [57, 58].  
 
In the LP some MNP are found relatively close to the epithelium and it has been 
suggested that these cells could extend processes into the epithelium to capture 
antigen directly from the lumen [59, 60]. Although it initially was thought that these 
cells were DCs, there is now a growing consensus that these cells are in fact 
macrophages expressing low levels of CD11c, MHCII and high levels of CX3C-
Chemokine receptor 1 (CX3CR1) [61]. It has been further suggested that the 
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macrophages are capable of transferring these captured antigens to DCs, via gap 
junctions, as they themselves are not able to migrate to adaptive immune induction 
sites during homeostasis [62, 63]. Moreover, colonic DCs were recently found to 
receive antigens via goblet cell-associated antigen passages (GAPs) [64] an event that 
was already known to occur in the small intestine [65]. Alternatively, some subsets of 
DCs have been shown to capture antigen directly from the lumen by penetrating the 
epithelial monolayer while forming tight junctions with surrounding epithelial cells to 
prevent breaching of the epithelial barrier [18, 66]. While many mechanisms of 
antigen uptake have been proposed, whether these different uptake mechanisms lead 
to the initiation of distinct adaptive immune responses remains unclear. 
 
2.2 Immune activation in the intestinal draining lymph nodes 
Upon capturing of antigen by DCs a cascade of intracellular events results in the 
presentation of processed antigen on major histocompatibility complex (MHC) class I 
or class II. This process leads to functional maturation of DCs, which prepares the DC 
for their prominent role as professional antigen presenting cells to mediate activation 
of naïve T cells. During this maturation process, DCs upregulate co-signaling 
molecules on its surface, of which the CD80/CD86 complex is the best characterized 
[67]. Furthermore, activation of DC within the LP upregulates expression of the 
chemokine receptor CCR7 [68], which is required for their migration via afferent 
lymphatics to intestine-draining mesenteric lymph nodes (MLN), and also drives DC 
localization into the LN T cell zones [69]. DCs present their antigen via MHCI to 
CD8+ T cells and on MHCII to CD4+ T cells. In Chapter 3 I will go deeper into this 
mechanism, where I also summarize our current knowledge about the differential 
roles of DC subsets in T cell activation.  MHC:peptide-complex interaction with the 
corresponding T cell receptors (TCR), co-stimulatory molecules (e.g. binding of 
CD80/86 to CD28 complexes on the T cell surface) and activating cytokines ensure 
the priming of naïve T cells into CD8+ cytotoxic or CD4+ T helper cells. This process 
leads to clonal expansion of antigen-specific T cells and the generation of effector and 
memory T cells. During this process, T cells that are primed in intestinal inductive 
sites also acquire expression of homing receptors, allowing them, once in the 
circulation, to efficiently enter intestinal effector sites. Homing to the small intestine 
is dependent on the chemokine receptor CCR9, which binds to CCL25 that is 
constitutively expressed by small intestinal epithelial cells, and integrin α4β7 whose 
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ligand mucosal vascular addressin cell adhesion molecule 1 (MAdCAM1) is 
constitutively expressed by vascular endothelium within the intestine [70-72]. 
Imprinting of small intestinal-homing molecules occurs preferentially in intestine-
associated inductive sites, and is thought to be dependent on retinoic acid (RA) 
production by small intestinal-derived cDCs and local stromal cells [73, 74]. 
Although less clearly defined, recent studies have linked G-coupled receptor 15 
(GPR15) to T cell extravasation to the colon, which responds to its proposed ligand 
GPR15L that is highly expressed in the human and mouse large intestine [75-77].  
 
2.3 Immune activation in GALT 
IgA is the most abundant class of antibodies found in the intestinal lumen, and is part 
of the first line of defense protecting the intestinal epithelium from enteric pathogens 
and toxins. Luminal IgA also has a key role in the maintenance of diversity in the gut 
bacterial community [78]. The main site of B cell differentiation into IgA producing 
plasma cells is the GALT [79]. Secretory IgA production is almost completely 
dependent on the presence of the microbiota that gets sampled into the GALT via M 
cells as described in chapter 2.1 [4]. In the GALT, naïve B cells undergo class 
switching and become IgA+ B cells, with the support from T follicular helper cells, 
and acquire homing potential to the intestinal LP. This event can also occur 
independently of T cell help, Mora et al. showed that GALT-DC derived RA, and IL-
6 and IL-5 work synergistically to induce class switching and imprint gut tropism in 
naïve B cells [80]. Activated IgA+ B cells migrate into the MLN, where they further 
proliferate and differentiate into IgA secreting plasmablasts that via the circulation 
extravasate into the intestinal LP [78, 81]. In the intestinal LP IgA is transported via 
endocytosis to the intestinal lumen upon binding to the epithelial polymeric Ig recptor 
(pIgR) [82].  
 
2.4 Adaptive immune populations in the intestine  
The intestinal effector tissues, the epithelium and LP, contain the body’s largest pool 
of T cells. The LP and epithelium contain both CD8+ and CD4+ T cells, although 
CD8+ T cells preferentially reside within the intestinal epithelium. The large majority 
of these cells has an effector memory phenotype and is thought to derive from naïve 
conventional T cells that have been primed in intestine-associated lymphoid organs, 
as described in the previous paragraphs. The CD4+ T helper population in the healthy 
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intestinal LP consists primarily of Th1, Th17 and FoxP3+ regulatory T cells, with few 
if any Th2 cells whereas the CD8+ T cells are primarily cytotoxic T lymphocytes 
(CTL).  
 
2.4.1 T helper cells 
Th1 cells are characterized by their production of IFNγ and are involved in cellular 
immunity against intracellular microorganisms and anti-tumor immunity [83, 84]. IL-
12 and IFNγ promote the polarization of CD4+ T cells into a Th1 phenotype through 
signal transducer of activated T cells (STAT)1 and STAT4 signaling [63, 83, 85]. 
This cascade activates the T-box transcription factor T-bet, which drives the 
differentiation program of Th1 cells [86, 87]. Natural killer (NK) cells and Th1 cells 
are the main sources of IFNγ in Th1 differentiation and in both cell types T-bet 
promotes the IFNγ production [88, 89]. Furthermore, recent studies found that IL-27 
is able to induce Th1 differentiation through STAT1 signaling in the absence of IL-12 
[90]. 
 
Th17 cells are present in higher numbers in the intestine compared to non-intestinal 
sites and the discovery of this subset has changed the classical Th1/Th2 hypothesis 
[91-93].  Th17 cells are characterized by the expression of IL-17A, IL-17F and IL-22 
and have a protective role in infections with fungi and extracellular bacteria [94]. IL-6 
and TGFβ stimulate a cascade that leads to STAT6 signaling which drives the 
differentiation of Th17 cells that is regulated by transcription factor retinoic acid 
receptor related orphan receptor gamma (RORγt) [95-97]. Although IL-23 is not 
involved in Th17 differentiation it is important in the maintenance of its (pathogenic) 
effector functions [95]. More recently IL1β has been indicated as a potential inducer 
of Th17 differentiation [32, 98]. The microbiota is key to the generation of intestinal 
LP Th17 cells as these cells are largely missing from the intestine of germ free mice 
[99-101]. 
 
2.4.2 T regulatory cells 
T regulatory cells are, as their name suggests, important in regulating immune 
responses by promoting tolerance to self- and foreign antigens and in dampening 
effector T cell responses during clearance of infection to limit autoimmunity and 
immunopathology. The intestinal Treg population contains thymic-derived natural 
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Tregs (nTregs) and peripherally induced Tregs (pTregs), also known as induced Tregs 
(iTregs), both of which are characterized by their expression of the transcription 
factor forkhead box protein 3 (FoxP3). Intestinal pTregs are believed to be generated 
from naïve CD4+ T cells in intestinal inductive sites, through the action of TGFβ and 
retinoic acid (RA) [102, 103]. Several studies have suggested that nTregs can be 
distinguished from pTregs by their expression of the ikaros family member Helios 
and trans-membrane protein neuropilin-1 [104-109], although Helios expression may 
not unambiguously separate natural from peripheral Tregs [110, 111]. In the intestine 
an additional subset of induced Tregs, termed Tr1, can be identified that is 
characterized by its abundant production of IL-10 and lack of Foxp3 expression [112]. 
These Foxp3-Tregs are like other pTregs dependent on TGFβ and are found in high 
numbers in the small intestine but are rare in the colon [112].  
 
Foxp3+ pTregs accumulation in the colon, but not small intestine, appears at least 
partially dependent on the microbiota as germ-free mice have reduced numbers of 
colonic Foxp3+ pTregs [113, 114].  Colonization of germfree mice with certain 
bacterial strains, most notably clostridia species leads to a strong increase of colonic 
pTregs cells but not nTregs [113-115]. Mice with reduced pTregs through deletion of 
RORc in FoxP3+ Tregs mounted a stronger Th2 response to intestinal helminth 
infections [107], deletion of pTregs however also resulted in Th2 induced pathology 
upon oxazolone-induced colitis [107]. Furthermore, mice deficient in conserved non-
coding DNA sequence 1 (CSN1), a promoter that is dispensable for nTregs but crucial 
for iTreg development, developed spontaneous Th2 induced intestinal pathology and 
altered microbial communities [116]. Luminal metabolites such as vitamin A derived 
RA, vitamin D3 as well as short chain fatty acids produced through the fermentation 
of dietary fibers by the microbiota [107, 115] also seem to promote the generation, 
maintenance and function of intestinal Tregs. In contrast to the colon, the majority of 
pTregs in the small intestine is dependent on dietary antigen [117]. Although germ 
free mice were devoid of pTreg in the colon, pTregs were present in the small 
intestine of these mice, but upon being fed an elemental diet devoid of dietary 
antigens pTregs gradually decreased in the small intestine as well [117]. Absence of 
dietary antigen resulted in increased intestinal allergic pathology upon oral OVA 
stimulation after OT-II transfer [117]. The importance of Tregs in intestinal 
homeostasis has been demonstrated in a large number of studies. Colitis induced by 
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the transfer of naïve CD4+CD45RBhi T cells in Rag deficient mice could be prevented 
or reversed by co-transfer of CD4+CD25+CD45RBhi Tregs [118]. Moreover RORγt+ 
pTregs showed enhanced suppressive capacity in T cell transfer colitis compared to 
RORyt- nTregs [108]. Furthermore depletion of Foxp3+ Tregs resulted in autoimmune 
inflammation and colitis that could be overcome by adoptive transfer of Foxp3+ Tregs 
[119].  
 
2.4.3 T cells in the intestinal epithelium 
Intraepithelial lymphocytes (IELs) are, at least in the mouse, a highly heterogeneous 
population, of predominantly CD8+ T cells. CD8+ IELs comprise of conventional 
CD8αβ+TCRαβ+ T cells (major population in humans) and unconventional CD8αα+ 
IEL that express either the γδ or αβ TCR [120]. All IELs express the integrin 
αE(CD103)β7, that binds to E-cadherin on the basolateral surface of  intestinal 
epithelial cells [121], promoting their localization, maintenance and function.  
 
Unconventional IELs develop in the thymus through positive selection on self-antigen 
and migrate directly to the intestinal epithelium. They populate the epithelium already 
at birth and this occurs independently of the microbiota or recognition of othere 
exogenous antigens [122, 123]. CD8αα is thought to function as a negative regulator 
of the MHC-TCR activation complex which may confer their mostly quiescent 
behavior [124]. CD8αα+TCRγδ+ IELs have been implicated in several processes; they 
can condition and repair the epithelial barrier, control IEC cell growth and turnover 
but also provide front-line defense against pathogenic enteric pathogens [120] while 
CD8αα+TCRαβ+ IELs have a potent antigen-experienced cytotoxic effector phenotype 
with high affinity to self-antigens and are believed to be important in front-line 
defense against invading pathogens and the maintenance of epithelial barrier integrity 
[121, 125]. Both subsets are thought to contribute to protective immunity by killing 
infected or injured cells by their cytotoxic phenotype [120, 126, 127].  
 
In contrast, conventional IELs like LP effector T cells are thought to encounter their 
cognate antigen in the LNs and subsequently migrate to the epithelium. Conventional 
CD8αβ+ TCRαβ+ IELs mainly express a cytotoxic effector memory phenotype, while 
CD4+TCRαβ+ IELs can embody all Th subsets [125]. Conventional IEL numbers 
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increase with age and are dependent on the microbiota [123]. Protection against 
viruses that have evaded CD8αβ+TCRαβ+ IEL recognition can be provided by a 
subset of CD4+ IELs that develop a cytotoxic phenotype and, upregulate CD8α, these 
cells can be found in the epithelium as CD4+CD8αα+TCRαβ+ T cells [128-130]. Most 
effector cytotoxic T cells carry out antigen specific killing of infected cells or 
neoplastic cells by inducing apoptosis via Fas-FasL, pore formation via perforin 
secretion or lysis by release of granzyme B [131]. 
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Chapter 3 Intestinal dendritic cells 
By the 1960s it was known that lymphocytes are the main players in adaptive 
immunity, it was however unknown how antigens stimulated these lymphocytes. In 
1973 Ralph Steinman and Zanvil Cohn first described a 'large stellate cell' in their 
splenocyte preparations [132]. The cell was termed "dendritic" and in later studies it 
was demonstrated that these cells possessed the unique capacity to stimulate naïve T 
lymphocytes [133]. These first studies by Ralph Steinman were subject of discussion 
and disregard, mostly because of the inability of other groups to reproduce their 
lymphocyte stimulating properties and their similarities to macrophages that were 
discovered already in 1884 [134, 135]. In the mid 80s the importance of classical DCs 
(cDCs) in immunological processes started to become more widely appreciated [135]. 
Ralph Steinman was awarded the Nobel Prize in physiology or medicine in 2011 for 
his discovery of cDC, unfortunately 3 days after his passing.  
 
cDCs are a minor cell population of hematopoetic origin that populate most lymphoid 
and non-lymphoid tissues. In peripheral tissues they reside in an immature state and 
are characterized by dynamic extensions that allow these cells to 'sweep' the 
environment and act as motile sensors, scanning the local environment for foreign and 
self-antigens. The identification of surface markers that are expressed on monocyte 
derived cells and not on cDCs, including CD64, F4/80 and MerTK has made it easier 
to more definitively identify cDCs in tissues [136, 137]. Currently cDCs in intestinal 
tissues are identified by their expression of MHCII, the integrin subunit CD11c and 
lack of monocyte/macrophage expressed high-affinity IgG receptor FcγR1, CD64 
[137-139]. Initially all CD11c+ cells were classified as cDCs, this included a subset of 
CX3CR1hi macrophages that was discussed in chapter 2.1, later studies however 
revealed that these cells were derived from the monocyte lineage and are now broadly 
classified as macrophages by their expression of CD64 [137, 140, 141]. Both 
monocyte derived cells that are especially present in inflamed tissue and a subset of 
cDCs express intermediate levels of CX3CR1, while resident macrophages express 
high levels of CX3CR1, which was identified by using CX3CR1-GFP mice [140, 142, 
143]. Across tissues cDCs can be subdivided in two main branches: cDC1 that 
express the chemokine XC receptor 1 (XCR1) and cDC2 that express the signal 
regulatory protein α (SIRPα) [144]. Depending on the tissue cDC1 and cDC2 can be 
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further subdivided based on additional markers; this will be discussed in more detail 
in chapter 3.3. 
 
3.1 Dendritic cell ontogeny 
cDC originate from pluripotent hematopoietic stem cells (HSCs) in the bone marrow 
(BM). The earliest progenitor that is committed to the mononuclear lineage is the 
macrophage dendritic cell progenitor (MDP) that are characterized by their expression 
of macrophage colony stimulating factor receptor (M-CSFR), fms-like tyrosine kinase 
3 (Flt3) and high levels of hematopoietic stem cell growth factor receptor C-kit 
(CD117) [145]. MDPs give rise to common DC progenitors (CDPs) that are C-
kitint/loFlt3+M-CSFR+ and give rise to exclusively pre-cDCs and pre-plasmacytoid 
DCs (pre-cDCs) [145-147].  CDPs that lost their expression of M-CSFR are thought 
to predominantly give rise to pre-pDCs, whereas CDPs that gave rise to cDCs 
maintained their expression of M-CSFR [148]. Pre-cDCs are capable of entering the 
blood stream and migrate into peripheral tissues, and they moreover express cDC 
markers CD11c and Zbtb46 [147, 149-151]. The differentiation of pre-cDCs into 
either cDC1 or cDC2 lineage was believed to take place in peripheral tissue with their 
downstream phenotype and functionality shaped by the local microenvironment [147, 
152]. Recent findings however indicate that many pre-cDC are committed to the 
cDC1 and cDC2 lineage already within the BM [153]. Single CDP cultured in vitro 
were found to preferentially develop into either cDC1 or cDC2 subsets [154]. 
Subsequent studies using single cell RNA sequencing and single cell clonal assays 
showed that BM pre-cDCs preferential cDC1 or cDC2 lineage commitment could be 
predicted based on differential expression of SiglecH and Ly6C; SiglecH-Ly6C+ pre-
cDC giving rise to cDC2, while SiglecH-Ly6C- cells being committed to the cDC1 
lineage [153].  
 
The differentiation of cDCs from HSCs is largely dependent on the cytokines Flt3 
ligand (Flt3L), and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
[151, 155]. GM-CSF is not crucial for cDC differentiation in the steady state as GM-
CSFR deficient mice only have a minor reduction in cDC numbers, it has however 
been indicated to act synergistically with Flt3L in DC development [156, 157]. Flt3L 
and GM-CSF control the initial production and lineage diversification of cDC. The 
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specific factors that regulate the expression of receptors for these key cytokines are 
however not fully elucidated. Moreover, Flt3L has also been indicated to maintain 
cDCs in peripheral tissues [158]. As discussed below cDC1 and cDC2 undergo 
further phenotypic changes depending on the tissue in which they reside. 
 
3.2 Intestinal dendritic cells  
Recent years have seen major advances in our understanding of the complexity and 
functionality of intestinal cDCs. In addition to XCR1 and SIRPα, intestinal cDCs can 
be subdivided based on expression of the integrin alpha chains CD103 and CD11b 
[136, 159, 160]. XCR1+ cDC1 are primarily CD103+CD11b-, while SIRPα+ cDC2 can 
be divided into CD103+CD11b+, CD103-CD11b+ cDCs [136]. In the steady state 
intestine a minor population of poorly defined CD103-CD11b- cDC can also be found, 
which appears heterogeneous in that they contain both XCR1+ and SIRPα+ cDCs 
[136]. cDCs are found throughout the intestinal LP, and within intestinal inductive 
sites. Within the LP the cDC1: cDC2 ratio is similar along the length of the intestine 
although CD103+CD11b+ cDC2s are found in higher frequencies in the small intestine 
while CD103-CD11b+ cDC2s are more common in the colon [4, 136]. Recent findings 
showed that CD103-CD11b+ cDCs can be further subdivided in CCR2- and CCR2+ 
populations [161] suggesting further heterogeneity within the intestinal cDC2 
compartment.  
  
Similar to all lymph nodes, intestinal draining MLN contain cDC1 and cDC2 of 
distinct origins, a lymph node resident population that enter the lymph node directly 
from the blood, and a LP derived migratory population. It has been proposed that 
under steady state conditions these populations can be distinguished based on their 
expression of MHCII with lymph node resident cDCs expressing lower levels of 
MHCII [162, 163].  
 
3.3 Intestinal dendritic cell ontogeny 
The first realization of heterogeneity in cDC population came with the discovery of 
CD8α+ and CD8α- cDCs in the spleen and thymus [164]. Almost 2 decades later our 
understanding has grown substantially but across tissues these 2 cDC subset are still 
recognized as the main branches of cDCs. We can now however further separate these 
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branches into subsets with distinct and overlapping functionality based on a broader 
panel of transcription factors and surface markers.  
 
3.3.1 (Intestinal) cDC1 development 
The development of intestinal cDC1 has not been as widely studied as intestinal cDC2 
development. In this chapter I will therefore discuss factors that are identified to be 
involved in intestinal cDC1 development and factors that were shown to be involved 
in cDC1 development on other peripheral tissues but could possibly apply for 
intestinal cDC1. 
 
Intestinal cDC1 development: The development of intestinal CD103+CD11b- cDC1, 
as in other peripheral tissues, is dependent on the transcription factors interferon 
regulatory factor 8 (IRF8), DNA-binding protein inhibitor-2 (Id2) and basic leucine 
zipper ATF-like transcription factor 3 (BATF3) [159, 165, 166]. Here IRF8 is the key 
transcription factor that acts upstream of Id2 and BATF3, and is critical for the 
lineage commitment of cDC1. Mice with a specific deletion of IRF8 in CD11c+ or 
ZBTB46+ cells lack all intestinal CD103+CD11b- cells [166, 167]. LN resident CD8α+ 
and lung tissue CD103+ cDCs require 2 alleles of IRF8 whereas the development of 
CD103+CD11b- cDCs appears unaffected in mice carrying only one copy of the IRF8 
allele, indicating that dependence of cDC1 on IRF8 differs between tissues [166, 168, 
169].  
 
Peripheral tissue cDC1 development: IRF8 induces the expression of pan-cDC1 
markers such as XCR1, and CLEC9A, while Id2 and BATF3 further enhance their 
expression [170, 171]. In a DC progenitor like cell line IRF8 expression has been 
shown to activate the expression of Id2 and BATF3 and facilitates the functional 
maturation of cDC1s by activating TLR signaling pathways [171]. Moreover Id2 and 
BATF3 expression alone were not sufficient for directing cDC1 development [171]. 
BATF3 acts later in the development and does not affect the development of CDPs or 
pre-cDCs, it has however been shown to be important for the cross-presenting 
capacity of cDC1s [165, 172]. Interestingly, during intracellular infections in Batf3-/- 
mice, cDC1s can develop independently of BATF3 [173]. It was shown that IL-12 
production in response to IFNγ restored cDC1 numbers and CD8+ T cell responses 
due to compensation by BATF [173]. IRF8, Id2, BATF3 and possibly other 
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transcription factors seem to have important roles in different stages of cDC1 
development and act in a synergistic fashion to facilitate cDC1 development and 
functionality. Id2 is also expressed by all cDC subsets with the highest expression in 
cDC1s, it is thought that Id2 acts as a inhibitor of pDC-lineage specifying 
transcription factor E2-2 and thereby promoting the development of cDCs [170, 174]. 
 
3.3.2 Intestinal cDC2 development 
Intestinal cDC2 appear far more heterogeneous than cDC1, and their characterization 
has been to some extent hampered by the fact that they share certain markers with 
monocyte-derived populations. Intestinal cDC2 cells express CD11b and SIRPα but 
lack expression of XCR1, DNGR-1 and CD8α [136, 175, 176]. Intestinal 
CD103+CD11b+ cDCs depend, at least in part on the transcription factors IRF4, 
kruppel like factor 4 (KLF4) and receptor neurogenic locus notch homolog protein 2 
(NOTCH2) for their development and/or survival [177-179]. IRF4 deletion in CD11c+ 
cells leads to a 50% reduction of CD11b+CD103+ cDCs in both small and large 
intestine and an almost complete reduction in the MLN [177]. The remaining 
CD103+CD11b+ cDCs in the small intestine in CD11c-Cre.Irf4fl/fl mice showed 
decreased survival in vitro, indicating that IRF4 is supporting survival of 
CD103+CD11b+ cDCs [177]. Moreover, CD11c-Cre.Irf4fl/fl mice displayed a 
reduction in CCR2+ CD103-CD11b+ cDCs [161]. Recently the transcription factor 
zinc finger E box-binding homebox 2 (Zeb2) was found to be expressed on pre-
cDC2s and cDC2s but was down regulated on pre-cDC1s and cDC1s [153, 180]. 
Zeb2 regulates commitment towards cDC2 by repressing Id2 [181]. In mice that 
lacked expression of Zeb2 on CD11c+ cells CD103-CD11b+ cells were decreased in 
the small intestine but not the MLN whereas CD103+CD11b+ cells were unaffected 
[181]. Interestingly there seems to be a potential relationship between the cDC2 
subsets, in mice lacking TGFβRII in CD11c cells CD103+CD11b+ cDC were 
dramatically reduced with a reciprocal accumulation of CD103-CD11b+ cDCs [182]. 
It was proposed that CD103-CD11b+ are immediate pre-cursors to CD103+CD11b+ 
cDCs and that this developmental stage is under control of TGFβ [182]. It however 
remains to be determined where in the developmental stage TGFβ signaling is 
required for the development of CD103+CD11b+ cDC2s. Different transcription 
factors and soluble factors might act in different stages of cDC2 development and due 
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to the heterogeneous nature of cDC2s the different transcription factors might work 
synergistically in the development of functionally different subsets.  
 
3.4 Intestinal dendritic cell functionality 
3.4.1 cDC1 functionality 
cDC1s can present endogenous antigen, such as viral proteins that are degraded in the 
cytosol and transported to the endoplasmic reticulum from where they get loaded onto 
MHCI. Or they can cross-present, a process in which exogenous antigen gets 
phagocytozed and either gets degraded in phagosomes from which they are directly 
loaded on MHCI or the phagocytosed antigen is exported to the cytosol and is 
processed as described for endogenous antigens. This process of cross-presentation is 
important in protection to intracellular infections and in the elimination of tumor cells. 
 
Studies using CD11c.cre.Irf8fl/fl and XCR1-DTA mice have identified an important 
role for cDC1s in intestinal adaptive immune homeostasis [166, 183]. These mice 
have reduced numbers of small intestinal LP CD4+ and CD8+ T cells and both studies 
found a major reduction in some subsets of small intestinal CD8+ IELs [166]. Ohta et 
al. suggested that cross talk of XCR1 on cDCs and its ligand XCL1 on T cells was 
important for overall survival and maintenance of LP and IEL T cells [183].  XCL1 
and XCR1 cross-talk enhanced survival of intestinal T cells by upregulating CD103 
and CD62L and in turn continued XCL1 expression on T cells enhanced cDC 
maturation and CCR7 upregulation enabling their migration to MLNs [183]. 
Moreover migratory cDC1 in the MLN are the major source of retinoic acid (RA), 
which is a key inducer of CCR9 and α4β7 that enables activated T cell to home to the 
small intestine [73, 166]. Possibly, the reduced migration capacities of primed T cells 
resulted in a reduction of conventional CD8αβ+ and CD4αβ+ T cells in the LP [166]. 
However, the effect that absence of cDC1 cells has on the T cell homeostasis in the 
large intestine remains to be explored.  
 
CD11c-Cre.Irf8fl/fl mice have normal proportions of Th17 and FoxP3+ Tregs in the 
small intestine, while they completely lack Th1 cells [166]. In the colon Th17 cells 
were also unaffected in CD11c-Cre.Irf8fl/fl mice, while FoxP3+ Tregs were slightly 
reduced and Th1 cells were absent [166]. This is consistent with other studies 
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showing that mice lacking cDC1s have an impaired response to colonic helminth 
infections, to infections with intracellular pathogens and have increased resistance to 
DSS induced colitis due to impaired Th1 responses or reduced IFNγ production [184-
186].  
 
Finally, Esterhazy et al. demonstrated that priming of FoxP3+ pTregs in response to 
dietary antigens is reduced in Zbtb46-Cre.Irf8fl/fl mice, indicating that cDC1s are 
involved in the generation of pTregs [167]. Although the reduced pTreg generation in 
Zbtb46-Cre.Irf8fl/fl mice did not result in impaired tolerance towards dietary antigen, 
which may be dependent on nTregs that are possibly not affected in these mice. 
 
3.4.2 cDC2 functionality 
As pointed out in chapter 2.3 cDC2s are a far more heterogeneous population of cDCs 
compared to cDC1s, and the lack of a mouse model that can selectively deplete all 
cDC2s makes it more challenging to identify and compare functional properties of 
cDC2 subsets. However some of the existing mouse models may cause impaired 
functionality in all cDC2s without depleting all of them.  
Studies using mice that lack expression of IRF4 or Notch2 on CD11c+ cells or SIRPα-
/- mice all show selective reduction in intestinal Th17 cells [161, 176, 177, 179, 187] 
and huLangerin-DTA mice, which lack CD103+CD11b+ cDC2s, have reduced 
numbers of small intestinal Th17 cells [188]. IRF4 has been indicated as an important 
promoter of MHCII antigen processing machinery in cDC2 [189]. Both the absence of 
CD103+CD11b+ and/or impaired MHCII antigen processing may lead to reduced 
amounts of Th17 cells in mice lacking IRF4 dependent cDC2s [175, 176, 189]. While 
in most of these models the underlying mechanisms of reduced Th17 number remains 
to be elucidated, one contributing factor might be that cDC2s produce IL-6 that may 
enhance the Th17 differentiation in the MLN [177]. Interestingly, mice that have 
specific deletion of Klf4 in CD11c+ cells have normal intestinal Th17 responses [178]. 
Indicating that Klf4 only affects a subset of IRF4 dependent cDC2 cells that does not 
entail Th17 promoting cDC2s; in contrast CD11c-cre.Klf4fl/fl mice have impaired Th2 
responses towards Schistosoma mansoni [178]. Consistent with this CD11cCre.Irf4fl/fl 
mice fail to induce a Th2 response towards parasitic worms Nippostrongylus 
brasiliensis or Trichuris muris [186, 190, 191]. While CD103+CD11b+ cDC2s were 
important in protective immunity towards Schistosoma mansoni in the small intestine, 
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CD103-CD11b+ cDCs performed this role in the large intestine [190]. These studies 
suggest that IRF4 and KLF4 dependent cDC2s are required for the development of 
Th2 immunity, while the mechanisms behind this remain to be elucidated. Infection 
with Trichuris muris in CD11c-cre.Irf4fl/fl leads to reduced expression of Th2 related 
cytokines such as IL-13, IL-4 and IL-5, which may lead in combination with impaired 
function of MHCII antigen processing to reduced Th2 responses [186, 189]. In 
contrast to mice with CD11c specific KLF4 deletion, Notch2 deficient mice can drive 
normal Th2 responses but are impaired in driving Th17 responses [179], indicating a 
functional heterogeneity in cDC2. 
 
Finally, although cDC1 were superior in inducing pTreg in response to dietary 
antigen, the same study by Esterhazy et al. showed that CD103+CD11b+ cDC2s 
isolated from MLNs could induce differentiation of OT-II cells into pTregs in vitro 
[167].  Moreover, huLangerin-DTA x BATF3-/- mice that lack both CD103+CD11b- 
cDC1 and CD103+CD11b+ cDC2s have reduced (CCR9+) Treg numbers in the small 
intestine but not the MLN [188], indicating that both subsets, which are mutually 
redundant for Treg induction, are jointly required for imprinting of a gut homing 
signature in Tregs. Thus the intestinal mucosa contains several cDC subsets, that 
appear to play distinct and possibly complementary roles in intestinal adaptive 
immune homeostasis.  
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Chapter 4 Inflammatory bowel disease  
Inflammatory bowel disease (IBD) is the collective name for different chronic 
inflammatory disorders of the intestine. Crohn’s disease (CD) and ulcerative colitis 
(UC) are the main types of IBD. Both CD and UC lead to long-term and sometimes 
irreversible damage to the intestinal epithelium [192], however they target different 
regions of the intestinal tract, and have distinct pathology. CD can affect any part of 
the gastrointestinal tract, although it is commonly concentrated to the terminal ileum. 
In CD transmural inflammation is more common, in combination with a thickened 
mucosa where aggregation of macrophages form granulomas [193, 194]. In contrast, 
UC is mostly restricted to the distal colon [192, 195], with a more superficial 
inflammation that is limited to the mucosa and submucosa, and can lead to cryptitis 
(inflammation of the crypts) and crypt abscess formation through accumulation of 
neutrophils in the lamina propria. The symptoms associated with IBD include 
diarrhea, fatigue and weight loss; furthermore, while abdominal pain is more common 
in CD, bloody stools predominantly occur in UC patients [196, 197]. Western Europe, 
North America and Australia have the highest reported prevalence of IBD worldwide 
[198]. However, prevalence of IBD is increasing worldwide, even in areas previously 
considered as low-prevalence regions, e.g. Asia, the Middle East and South America 
[196-198].  
 
4.1 Risk factors 
Several risk factors have been associated with IBD, including genetic predisposition 
and environmental and dietary factors. Genome-wide association studies (GWAS) 
have identified numerous risk loci for IBD. These include genes associated with 
intestinal barrier function, e.g. genes involved in autophagy and paneth cell function 
or tight junction formation [194, 199], as well as immune-related genes associated 
with innate or adaptive immunity, e.g. the recently identified polymorphisms in DC-
related genome regions (e.g. DEC-205 and CCL20) [199, 200], or genes involved in 
Th17 functionality or modulation of general components of T cell activation (e.g. 
AHR and CD28) [201]. These risk loci will be discussed in more detail in chapter 4.3 
(‘Innate immune system in IBD’). 
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Certain gene loci are a significant contributing factor for IBD pathogenesis such as 
NOD2, people carrying one high risk allele had 2.39 fold increased odds to develop 
CD and people carrying two copies of a high risk allele had an 17.7 fold increased 
risk for developing CD compared to people that carried no copies of high risk alleles 
[202]. Of all identified risk loci NOD2 has the highest contributing factor [202]. 
However, the fact that IBD is more common in certain geographical regions and that 
it increases rapidly in ‘genetically stable’ populations indicates that environmental 
factors have a major contribution. For example, epidemiological studies have 
demonstrated that IBD is more common in westernized regions with a lower 
prevalence in rural compared to urban areas [198, 203]. Furthermore, young 
immigrant populations migrating from low- to high-prevalence regions were shown to 
adopt a similar incidence rate compared to non-immigrant populations in the high 
prevalence regions [204].  
 
Increased allergies and autoimmune diseases such as IBD in the industrialized world 
has been associated with a decline in (childhood) infections, also known as the 
hygiene hypothesis [205, 206]. Consistent with this idea, childhood exposure to pets 
or living on a farm in combination with drinking unpasteurized milk and higher 
housing density have been correlated with reduced risk for developing IBD [207]. 
Although there is little doubt that environmental factors can contribute to the risk of 
developing IBD, many of the low prevalent regions are industrializing, this often is 
connected to improvement of healthcare and in combination with better knowledge 
about IBD diagnostics this might increase the amount of reported cases in certain 
regions.  
 
Dietary factors have however also been identified; increased risk for IBD was found 
to correlate with a high intake of sugar/sweeteners and fat-rich diets, while breast-
feeding and high intake of dietary fiber was correlated with reduced risk [208, 209]. 
The majority of these studies indicate dietary and other exposing factors that may 
influence the commensal microbiota, which is consistent with the emerging idea that 
cross-talk between the microbiota and the immune system is essential for maintaining 
immune homeostasis in the intestine [3, 210]. Exposure to antibiotics, especially in 
childhood, is hypothesized to alter development of tolerance to enteric bacteria, which 
may lead to IBD, while other studies have identified the use of antibiotics years prior 
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to IBD development as an increased risk [208, 209, 211]. Furthermore, decreased 
biodiversity and dysbiosis have been indicated as one of the driving forces in IBD 
[212]. Although some pathogens have been associated with increased risk (e.g. 
increase in adherent-adhesive Enterobacteriaceae), there are also members of the 
microbiome that have protective effects in IBD by for example down-regulation of 
inflammatory cytokines (e.g. Bifidobacterium, lactobacillus, faecalibacterium) [212, 
213]. Collectively, the above-mentioned studies show that environmental and dietary 
factors influence the intestinal immune system either directly or indirectly via the 
microbiota and this may lead to IBD in genetically susceptible individuals (see figure 
1. for a schematic overview). Moreover, in multiple mouse models of colitis such as 
Dextran sulfate sodium (DSS) induced colitis and T cell transfer colitis, germ-free 
mice develop no or only mild colitis [214, 215]. It is so far not known if colitis in IBD 
patients develops due to dysbiosis or if dysbiosis is a consequence of colitis, this may 
even differ between patients. 
  
 
 
4.2 Animal models for IBD 
Although animal models for IBD do not represent the complexity of the human 
disease, they have contributed greatly to our understanding of the underlying 
immunological mechanisms that drive and maintain chronic intestinal disease. This 
chapter will describe a selection of the most commonly used murine models of IBD 
including the T-cell transfer colitis model that was used for manuscript I. 
 
Figure 1. Schematic overview of factors that can lead to IBD. Genetic and environmental factors 
may lead to impaired intestinal barrier function, dysbiosis and inflammation, which together may 
result in IBD. 
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Chemically induced colitis: Chemically induced models are the most frequently used; 
they are simple and the onset of inflammation is rapid. Administration of DSS in 
drinking water results in symptomatic features that resemble UC [216]. DSS damages 
the epithelial barrier resulting in increased intestinal permeability, bacterial 
translocation and acute inflammation. Acute colitis is induced by one continuous 
cycle of DSS (4-9 days) and chronic colitis follows after administering low doses of 
DSS in consecutive cycles (7 days followed by water for 10 days) [217]. Colitis is 
accompanied by increased expression of inflammatory mediators (e.g. TNFα, IL-1β 
and IL-6, IFNγ), increased epithelial apoptosis, tight junction alterations and 
increased infiltration of inflammatory cells. Trinitobenzene sulphonic acid (TNBS) is 
injected rectally and like DSS disrupts the mucosal barrier, inflammation is induced 
by haptenization of colonic mucosal proteins [218]. TNBS colitis is characterized by 
Th1 driven inflammation [219]. Rectal administration of Oxazolone induces 
symptoms earlier in comparison to TNBS and is characterized by ulceration in the 
distal colon, resembling UC [220]. 
 
Innate anti-CD40 model of colitis: The model of anti-CD40 induced colitis in Rag-/- 
mice is particularly suitable to study innate immunity in colitis. Injection of agonist 
anti-CD40 monoclonal antibody, which resembles the CD40L on activated T cells, in 
Rag-/- mice results in acute innate driven colitis [221].  
 
Genetic models of colitis: IL-10 deficient mice develop spontaneous microbial 
induced colitis [222, 223], which is predominantly mediated by aberrant Th1 immune 
responses [224]. IL-10 is an important anti-inflammatory cytokine that directly 
inhibits macrophage and Th1 cell function [223]. TCRα deficient mice develop 
microbial driven colitis [225, 226] and a strong antibody response to self antigens 
[226]. Disease in TCRα deficient mice is characterized by type 2 immunity [224]. 
 
Adoptive transfer model: The model of CD4+CD45RBhi T cell transfer is probably the 
most suitable model to study CD4+ T cell driven colitis. Transfer of naïve CD45RBhi 
T cells into Rag-/- or severe combined immune deficient (scid) recipients results in 
severe chronic colitis, the transferred cells polarize and expand into Th1 and Th17 
cells upon interaction with microbiota derived antigen [227]. This model has been 
instrumental in identifying the T cell subsets that are driving IBD and the effector 
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cytokines driving and controlling this response. One of the key findings in the T cell 
transfer model of colitis is that colitis can be prevented or cured by co-transfer with 
CD4+CD25+CD45RBlo regulatory T cells [118]. Thus this model is also of use for 
understanding the mechanism of T cell mediated control of colitis. 
 
Pathogen induced models of colits: Rag-/- or scid mice adoptively transferred with 
CD4+CD45RBhi T cells or IL-10-/- mice that are infected with Helicobacter hepaticus 
develop severe colitis that is often accompanied with rectal prolapse [228]. Chronic 
intestinal inflammation in Helicobacter hepaticus infected colitic mice is 
predominantly Th1 driven, with elevated levels of TNFα, IFNγ and IL-12 [229]. 
Citrobacter rodentium is a mouse pathogen similar to entero-pathogenic Escherichia 
coli in humans [230]. C.rodentium that infects the ceacum in mice induces a strong 
mucosal Th1 response that causes pathology similar to Th1 driven IBD in humans 
[230]. 
 
4.3 Genetics and immunology of IBD 
As introduced in chapter 1, the intestinal tract is continually exposed to a large 
amount of foreign antigen such as food antigens, pathogens and commensal 
microbiota. The complex task of the intestinal immune system is to distinguish the 
beneficial antigens from the detrimental ones; failure in this balancing act, in 
combination with environmental factors and genetic predisposition, can result in 
inflammatory responses that may develop into chronic intestinal inflammation, 
including IBD. Several direct or indirect immune-related functions and pathways have 
been revealed by GWAS as risk loci for IBD [231]. This chapter will describe the 
main genetic risk factors and consequences of these mutations that are connected to 
the development and maintenance of IBD.  
 
4.3.1 innate immune system in IBD 
Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) (a.k.a. 
CARD15) was one of the first identified risk genes for IBD. Polymorphisms in this 
gene are common among IBD patients and have been associated with direct and 
indirect effects on innate immunity [199, 232]. NOD2 is a member of the PRR family 
that recognizes muramyl dipeptide (MDP), a component of bacterial peptidoglycan 
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[233]. NOD2 is broadly expressed by macrophages, dendritic cells and at lower levels 
in epithelial cells [233]. Activation of NOD2 by MDP results in TRAF6-mediated 
activation of the NF-κB pathway, leading to secretion of IL-1 and IL-8 [233, 234]. 
Most variants of NOD2 polymorphisms interfere with the ability of NOD2 to 
recognize its ligand [235], resulting in reduced capacity to induce NF-κB activation 
and IL-1 production upon stimulation with MDP [235]. Indeed cDCs derived from 
CD patients with NOD2 deficiencies have an impaired ability to produce IL-1α/β in 
co-culture with memory T cells [236]. Although it is indicated that NOD2 mutations 
can contribute to colitis in a large group of IBD patients [231], it remains to be 
elucidated  whether direct effects on NOD2 signaling by cDCs contributes to disease 
development. NOD2 has also been suggested to regulate responses via other PRRs 
such as downregulation of IL-12 production via TLR2 [235]. Indeed, the inability of 
NOD2 variants to downregulate TLR2-induced IL-12 has been suggested as a major 
contributor to aberrant the inflammatory response in CD [235]. Moreover in a model 
of necrotizing enterocolitis, activation of NOD2 inhibited TLR4-signaling and 
thereby ameliorated disease [237]. In the healthy murine and human colon DCs 
express low levels of TLRs and DC activation markers such as CD80 and CD86 [238-
240]. This is likely contributing to their relatively quiescent phenotype in homeostatic 
conditions [239, 241]. cDCs from IBD patients however have an activated phenotype, 
indicated by significantly elevated expression of TLR2, TLR4 [239]. Moreover, 
especially cDCs from inflamed tissues of IBD patients had increased expression of 
CD40 and showed enhanced production of IL-12, IL-6 compared to those from un-
inflamed tissues or healthy controls [239]. Whether this increased activity in cDC 
from IBD patients is related to NOD2 mutations has however not been assessed. 
 
More recently it was demonstrated that NOD2 signaling can induce autophagy ('self-
eating') at sites of bacterial entry, via ATG16L1 [242, 243]. Autophagy is another 
important cellular pathway that has not been explored in relation to IBD until 
relatively recently [244]. Autophagy occurs essentially in all cells of the body as a 
homeostatic function to regulate organelle turnover, but is upregulated in the event of 
starvation to generate intracellular nutrients and energy, and in order to remove cells 
that are damaged following intracellular infection, protein aggregate formation, 
accumulation of misfolded proteins, or oxidative stress [245]. Monocyte derived DCs 
from IBD patients with NOD2 polymorphisms have reduced autophagy and impaired 
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MHCII surface expression upon stimulation with MDP that resulted in diminished 
bacterial killing of adherent-invasive E.coli by DCs with NOD2 polymorphisms in 
vitro [243].  
 
Both NOD2 and ATG16L1 have also been implicated in IL-10 signaling pathways 
[246]. A gain-of-function variant of NOD2 polymorphism has been suggested to 
suppress IL-10 transcription [247] and monocytes from IBD patients with NOD2 and 
ATG16L1 polymorphisms had significantly impaired IL-10 production upon in vitro-
stimulation [246]. Moreover, children with functional mutations in IL-10 receptor 
(IL-10R) display severe IBD-like symptoms in the first years of their lives [248] and 
spontaneous microbiota-driven colitis also arises in IL-10-/- mice [23]. IL-10 is an 
important mediator for FoxP3+ Treg survival and it suppresses IL-23p19 and IL-
12p35 [22, 23, 143]. Furthermore, IL-10R on macrophages is essential for intestinal 
homeostasis as mice lacking IL-10R on macrophages develop spontaneous colitis [30, 
31]. Although these studies indicate important functions for NOD2 signaling and 
autophagy in regulating intestinal homeostasis, it remains to be determined whether 
polymorphisms in these genes directly lead to IBD. It is for example still unknown 
which cell types promote colitis in patients with NOD2 mutations.  
 
Ly75 that encodes for the endocytotic c-type lectin receptor 205 (DEC-205), a surface 
receptor that is highly expressed on DCs, is involved in the endocytosis of exogenous 
antigens and their presentation on MHC, is a relatively newly identified risk locus for 
IBD [199]. Although the mechanism in IBD patients with Ly75 polymorphisms 
remain to be elucidated, in experimental colitis targeting of DEC-205 that is 
expressed on immature DCs promotes FoxP3+ Treg proliferation [249, 250]. 
Targeting of DEC-205 leads to ameliorated disease in a model of villin specific 
CD4+FoxP3- Tcell induced colitis [249]. Another recently identified loci is CCL20 it 
encodes for the chemokine CCL20 that is expressed by intestinal epithelium and is 
involved in the recruitment of regulatory T cells and dendritic cell to the gut [251]. 
This chemokine is increased in the intestine of IBD patients [251, 252]. Moreover, the 
locus of its receptor CCR6 has also been associated with IBD [199]. The mechanisms 
by which CCL20 and CCR6 contribute to IBD remain to be elucidated, but in 
inflamed crypts of IBD patients it was shown that increase in CCR6+ DCs was 
positively correlated with a higher histological inflammatory grade [253]. CCR6 is 
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also involved in the homing of Th17 and Treg cells to the intestine [254], and 
interestingly transfer of Th17 cells from CCR6-/- donors resulted in severe Th1 
mediated colitis in Scid mice [254]. Interestingly, CCR6-/- mice were partially 
protected from DSS induced colitis [255]. 
 
Collectively these studies indicate that the innate immune system has a significant 
role in the onset and maintenance of IBD. Innate immune cells can create a pro-
inflammatory environment by secreting cytokines but they can also act as a mediator 
to attract other cells of the innate and adaptive immune system. (See figure 2. for an 
overview of immunological changes in IBD) 
 
4.3.2 Adaptive immunity in IBD 
Key insights from GWAS has implicated a role for the IL-23/Th17-axis in IBD [231, 
256]. For a long time, under the influence of the prevailing Th1/Th2 paradigm, UC 
was long considered a Th2-driven disease whereas Th1-immunity was suggested as a 
main driver of CD [193, 257-260]. However, with the discovery of Th17 cells [92], 
and that IL-12 shares the p40 subunit with IL-23, this picture has changed [261]. 
Furthermore, additional genes involved in Th17 differentiation have been revealed as 
IBD-associated loci [231, 262] and polymorphisms in the IL-23 receptor gene that 
result in enhanced signaling are highly correlated with an increased risk for IBD [194, 
231, 263]. As mentioned in chapter 2.4, IL-23 is not involved in the differentiation of 
Th17 cells but it is important for their maintenance and (pathogenic) effector 
functions [95]. In recent years the IL23/Th17 axis has been implicated in many 
immunopathological disorders including IBD [264, 265], and below is a summary of 
our current understanding of Th17 cells and IL-23 in intestinal pathology.  
 
Mucosal inflammation is characterized by the recruitment of monocytes from the 
circulation in response to upregulation of inflammatory cytokines and chemo-
attractants such as CCL2 [266, 267]. These monocytes can give rise to inflammatory 
macrophages and monocyte derived DCs (moDCs), which are both potent inducers of 
TNF, IL-12 and IL-23 [142, 143, 193, 268]. These moDCs and monocyte derived 
macrophages both in humans and mice are the main producers of IL-23 and in mice 
CD103+CD11b+ intestinal cDCs have also been shown to express IL-23 [143, 184, 
268, 269]. IL-23 binds to the IL-23R on Th17 cells and both in humans and mice 
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stimulates the production of IL-17, IL-21 and IL-22 and IL-6 [270, 271]. The IL-17R 
is widely expressed by immune cells but also by non-hematopoietic cells such as 
endothelial- and epithelial cells [272, 273]. Binding of IL-17 to the IL17R promotes 
pro-inflammatory cytokine production by intestinal epithelial cells such as TNF, IL1 
and IL-6 [273-275].  
 
The importance of IL-23 in intestinal inflammation has been confirmed by many 
studies in mouse models for experimental colitis. Spontaneous colitis in IL-10-/- mice 
was abrogated in the absence of IL-23p19, but not in the absence of IL-12p40 [276]. 
Colitis was also abrogated in the absence of IL-23p19 in a model of T cell-transfer 
colitis and Helicobacter hepaticus-infected mice treated with anti-IL-10R [277]. 
Initial experiments indicated that the pro-inflammatory actions of IL-23 was primarily 
mediated through its activities on Th17 cells, however more recently ILCs and 
unconventional γδT cells were also found to be responsive to IL-23 [278, 279]. In 
IBD patients RORγt+ ILCs that responded to IL-23 are a source of IL-17 in inflamed 
tissue [280] and γδT cells express Th17 related transcription factors such as RORγt 
and AHR, and can secrete IL-17 and IL-22 in the response to IL-23 and IL-1β [278, 
279, 281]. The involvement of innate immunity in IL-23 dependent colitis was shown 
in Helicobacter hepaticus-driven colitis in Rag-/- mice where colitis was abrogated in 
the absence of IL-23 [282]. The involvement of IL-23 in innate immune-driven colitis 
was later confirmed in the anti-CD40 model of colitis in Rag-/- mice [283], and it was 
suggested that RORγt+ ILCs drive IL-23 dependent intestinal pathology in the anti-
CD40 model of colitis [283]. These findings of ILC involvement in mouse models of 
colitis are however not yet confirmed in human disease.  
 
Group 1 T-bet expressing ILCs, that could produce IFNγ ex vivo, are present in 
higher numbers in inflamed intestinal tissues from CD patients [284]. Interestingly 
these IFNγ expressing ILC1s could develop from group 3 RORγt+ ILCs, indicating 
that there is a certain plasticity between the group 1 and group 3 ILCs [284]. Similar 
events have been identified in Th17 cells; especially in inflammatory conditions Th17 
cells can upregulate IFNγ under the control of IL-12 and IL-23 but in the absence of 
TGFβ [285-287]. Moreover, an increase in IL17+IFNγ+ T cells has been observed in 
patients with active IBD [288].  
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More recent studies indicated that IL-23 may not only act as a mediator of pro-
inflammatory Th17 cells, but can also act to reduce the amount of FoxP3+ Tregs in T 
cell-transfer colitis [289]. Transfer of naïve T cells in IL-23 deficient Rag-/- mice 
resulted in a significantly increased proportion of FoxP3+ T cells compared to transfer 
in IL-23 sufficient Rag-/- mice [289]. This indicates that apart from maintaining 
colitis-inducing Th17 cells, IL-23 may also act to suppress regulatory responses. Th17 
and FoxP3+ Tregs are developmentally related as TGFβ is required for the 
differentiation of both populations, and studies have indicated that the presence of 
STAT3-mediated signals, such as IL-6 and IL-23 promote Th17 cells at the expense 
of FoxP3+ Tregs [290, 291]. Furthermore, TGFβ-signaling is impaired in the inflamed 
intestine of IBD patients [292]. SMAD family member 7 (Smad7) associates with 
TGFβ and functions as an antagonist for TGFβ signaling [293]. The impaired TGFβ 
signaling was correlated with an increased expression of Smad7 [292, 294]. Blockade 
of Smad7 was shown to restore TGFβ-signaling in a patients with active IBD and 
although the effect on disease severity was not measured, mononuclear cells isolated 
from these patients showed decreased pro-inflammatory cytokine production after 
Smad7 treatment [292]. 
 
The notion that IL-23 is the main driver of intestinal pathology might be too 
simplified, as interplay of IL-23 and IL-12 has been shown to maintain chronic local 
and systemic inflammation in IBD and other chronic inflammatory diseases [221, 
295-297], and in CD patients both IL-23 and IL-12 are elevated [298, 299]. Thus, it 
has been suggested that IL-23 regulates local bacterial-induced inflammation in the 
colon, whereas IL-12 directs innate driven systemic inflammation [221]. Other 
cytokines may be involved as well, such as the more recent identified IL-21. IL-21 is 
increased in the inflamed intestine of IBD patients and is produced by both Th17 and 
Th1 cells [193, 194, 300]. Blocking of IL-21 suppressed the production of IFNγ and 
IL-17 by in vitro stimulated T cells isolated from IBD patients [300-302]. Moreover 
IL-21 deficient mice were protected from DSS- and trinitrobenzene sulfonic acid 
(TNBS)-induced colitis [302]. The pro-inflammatory effect of IL-21 may be enhanced 
by its ability to suppress Treg responses, as CD4+CD25+ Tregs treated with IL-21 
failed to prevent T cell-transfer colitis in Scid mice [303]. All these data together 
indicate that Th17 derived cytokines could have both detrimental and protective 
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effects, IL-23 seems to play a role in the regulation and maintenance of pro-
inflammatory effector roles of Th17 cells in IBD [256].  
 
Although in some patients a single gene defect can lead to severe early onset IBD, 
such as mutations in the IL-10 gene, in most cases IBD develops due to a combination 
of genetic pre-disposition, environmental influences and a slow disease development 
due to a change in barrier function, cell infiltration and function, and the cytokine 
environment. Together the studies mentioned above illustrate the immune complexity 
of IBD. (See figure 2. for an overview of immunological changes in IBD) 
 
 
 
4.4 Treatments for IBD 
There is no known cure for IBD, but anti-inflammatory drugs are frequently used in 
the treatment for IBD to help reduce symptoms and retain remission. The choice of 
Figure 2. An overview of the biological and immunological changes in IBD. In IBD, intestinal 
integrity is impaired through damage of the epithelium, and impaired function of paneth cells (less 
antimicrobial peptides) and goblet cells (impaired mucus production). Impaired barrier integrity 
results in dysbiosis and increased bacterial translocation. Classical dendritic cells (cDCs), 
macrophages and epithelial cells respond to the breach of the epithelium by producing pro-
inflammatory cytokines and chemokines. cDCs upon capturing intestinal (bacterial) antigen travel to 
the MLN to prime and imprint Th1 and Th17 cells with a gut homing signature. Increased levels of 
pro-inflammatory cytokines and chemokines attract monocytes from the circulation that develop into 
monocyte derived DCs (moDCs) and monocyte derived macrophages. moDCs and monocyte derived 
macrophages produce high levels of IL-23 that induces a pro-inflammatory Th17 response and 
inhibits Tregs function.  
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treatment is usually based on the current disease activity, severity and long-term 
prognosis in combination with negative responses or side effects in prior treatments 
[196, 197]. Mild disease is often treated with aminosalicylates and corticosteroids are 
prescribed for patients with moderate disease. Severe UC is often treated with 
cyclosporine and current treatment for severe fistulizing CD are biological 
therapeutics (e.g. anti-TNFα) [304]. Anti-TNF agents have been a major advancement 
in the treatment of severe IBD of which infliximab and adalimumab are the most 
frequently used and these are mostly the first biological treatment to be used in 
patients [305, 306]. Anti-TNFα antibodies neutralize soluble TNFα, induce apoptosis 
of- and block growth factors for activated T effector cells and inflammatory monocyte 
derived cells and they can induce regulatory macrophages in the local tissue [307, 
308]. Although anti-TNFα antibodies have proven to be effective and reasonably safe, 
despite earlier concerns [309], about one third of individuals are unresponsive to this 
treatment apart from the fact that it is relatively costly [305]. In long-term treatments 
patients can develop immunogenicity by generating anti drug antibodies, this could be 
overcome by administering immunosuppressive drugs simultaneously, even though it 
can lead to increased risk for infection and malignancy [304, 310, 311].  
 
Other biological agents that are investigated for IBD treatment are anti adhesion 
molecules (anti-α4β7), JAK inhibitors, anti IL-12/IL-23p40 antibodies and restoration 
of normal TGFβ signaling (SMAD7 blockage) [305, 312, 313]. Surprisingly despite 
pre-clinical indications that IFNγ and IL-17 play major roles in the maintenance of 
IBD, clinical trials were unsuccessful. Anti-IFNγ failed in clinical trails and anti-IL-
17 even leads to worse disease in CD [314, 315]. 
 
Microbiome modulators such as antibiotics, prebiotics (e.g. carbohydrates, short-
chain fatty acids), probiotics, special dietary formulations and fecal microbial 
transplantation are under investigation. Some trials have shown minor success but 
long-term effects of dramatic changes in the microbiota are unknown and large scale 
studies are needed to get a clear picture of what a healthy microbiome actually is 
[305, 316, 317]. 	
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Chapter 5 Colitis associated cancer 
IBD patients are at increased risk for developing colorectal cancer (CRC), either in 
sporadic form or as colitis associated CRC (CAC) [318-320]. CRC is the third most 
common cancer worldwide, and accounts for about 8% of cancer related deaths [320]. 
The risk for CRC in UC patients is 2% after 10 years, 8% after 20 years and 18% after 
30 years of active disease [321]. Later studies however found a decreasing risk of 
CRC in IBD patients [321, 322], which might be related with the improved treatments 
of IBD and better surveillance for dysplasia [323]. This risk for CRC in IBD patients 
is correlated with the severity of colitis, local inflammation and family history; IBD 
patients with primary sclerosing cholangitis and/or a family history of CRC are at 
high risk but patients without colonic inflammation and UC limited to the rectum 
have no increased risk for developing CRC [322, 324].  
 
5.1 Risk factors for colorectal cancer 
Although genetic factors have been implicated in sporadic CRC (e.g. mutations in the 
tumor suppressor APC gene), they are less clear defined in CAC where mutations 
mostly occur due to excess inflammation [325]. However approximately 5-10% of 
colon cancers are initiated by inheritable mutations [326]. CRC has like IBD been 
associated with a ‘western’ lifestyle, high consumption of animal fat, processed or red 
meat, low intake of vitamin D and a diet poor in fibre and fish have been linked to 
risk of CRC development [327, 328]. Some studies have reported association of 
dysbiois and the development of CRC [329] and some bacterial populations have 
been identified to be present in higher number in the CRC affected colon (e.g. 
fusobacterium) [330, 331]. The risk factors that contribute to CAC, are less well 
studied compared to sporadic CRC, as formation of cancerous lesions are more likely 
to result from chronic inflammation of the mucosa then from any clear-cut genetic 
predisposition. 
 
5.2 Animal models for CRC and CAC 
Genetic models: Mice carrying a heterozygous mutation in the APC gene rapidly 
develop tumors similar to patients with familial adenomatous polyposis. This model 
has been very helpful in understanding the polyp growth and progression and in the 
functional analysis of the APC gene product and mapping of the essential domains 
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[332]. About 60% of IL-10-/- mice develop tumors in the proximal colon and ceacum, 
these tumors do however not resemble human CRC or CAC, no alterations in the p53 
or APC gene or mismatch repair defects were found in these mice [333].  
 
Chemically induced models: Carcinogen induced models in mice are a valuable tool 
to assess phases of initiation and progression of tumors that occur in human CRC. 
Chemical induced models are relatively reproducible and can be applied to animals 
with different genetic backgrounds. The currently most common carcinogen used is 
Azoxymethane (AOM) [334]. Upon intra-peritoneal injection, AOM gets 
hydroxylated and forms the reactive metabolite MAM that can alkylate 
macromolecules in the liver and colon [335]. This process leads to methylation at the 
O6-position of guanine in the DNA molecule, which has been shown to be the 
primary pro-mutagenic lesion produced by AOM [335].  AOM induced tumors carry 
frequent mutations in K-Ras and β-catenin and less common microsatellite instability 
[334]. Administration of several cycles of DSS in combination with AOM 
dramatically decreases the latency time, causing rapid tumor growth within 10 weeks 
compared to 30 weeks with AOM administration alone [336]. In the AOM/DSS 
induced model of CAC tumors develop from aberrant crypt foci that develop into 
adenomas at about week 5-6 that form into carcinomas at about week 8-20 depending 
on the mouse strain [334].  
 
Pathogen induced models: IL-10 deficient mice that are infected with H.hepaticus 
develop tumors more rapidly compared to uninfected mice with IL-10 deficiency 
[337]. Tumors that formed in this model were comparable to AOM/DSS induced 
tumors in terms of morphology, invasiveness, or β-catenin mutations [337].  
 
5.3 Immunopathology of colitis associated cancer 
The inflamed colon in IBD patients is rich in reactive oxygen species (ROS) due to 
the infiltration of among others inflammatory macrophages which can cause DNA 
damage and exogenous mutations (e.g. microsattelite instability, CpG island 
methylation and microRNA alterations) facilitating the initiation of cancerous lesions 
[318, 338]. Cumulative effects of DNA damage and p53 (tumor suppressor) mutations 
results in continuous activation of Wnt/β-catenin signaling pathway, and formation of 
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adenomatous lesions in the colon, eventually resulting in the loss of the adenomatous 
polyposis coli (APC) tumor suppressor gene function [326]. P53 mutations occur in a 
later stage in large adenomas of sporadic CRC patients while in contrast in CAC 
cytokine stimulation drives the p53 mutation in inflamed mucosa in the early stage 
often before dysplasia occurs [323, 326] (see figure 3. for a schematic comparison of 
CRC and CAC).  
 
 
 
Impaired barrier integrity and epithelial cell damage due to chronic intestinal 
inflammation results in increased epithelial turnover and bacterial translocation. The 
fact that germ free mice have reduced tumor development [339] and that MyD88 
deficient mice have reduced tumor numbers indicates that PRR signaling is an 
important factor in CAC development [340]. PRR signaling initiates NF-κB mediated 
IL-6 production in myeloid cells that has been thought to activate STAT3, which is an 
important regulator of proliferation and survival of tumor-initiating intestinal 
epithelial cells (IEC) both in AOM/DSS induced CRC [341-345]. Moreover, STAT3 
activation by IL-6 (or alternatively by IL-22 and IL-23) has been implicated to 
regulate the tumor inflammatory environment directly by inducing pro-tumor gene 
Figure 3. Mechanism of colitis associated colorectal cancer (CAC) and sporadic colorectal 
cancer (CRC) development. CAC follows upon increased levels of pro-inflammatory cytokines, and 
increased STAT3 and NF-κB signaling. This can induce mutations in oncogenes such as APC and K-
Ras and genomic instability by for example methylation as seen in AOM/DSS induced colitis. 
Persistent inflammation facilitates tumor promotion by activating proliferation and anti-apoptotic 
properties of premalignant cells, as well as tumor progression and metastasis. CRC in contrast is 
caused by accumulation of mutations in oncogenes and tumor suppressor genes (e.g. APC) or 
aberrant activation of β-catenin. Mutations in APC or β-catenin, or other components in this pathway 
mediate the transition of single neoplastic cells to aberrant crypt foci (AFC) and then to 
adenocarcinoma and metastatic cancer.  
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expression programs such as the expression of angiogenic factors [341, 346, 347]. 
Consistent with this, epithelial cells from patients with active UC and patients that 
had progressed to CAC, expressed higher levels of IL-6 and phosphorylated STAT3 
protein expression [348]. In contrast, stimulation of STAT1 by type 1 interferons 
regulates expression of genes that inhibit growth and induce apoptosis of malignant 
cells [349]. The above studies indicate that signaling via STAT proteins shows to be a 
double-edged sword in tumor immunity, where signals such as IFNγ, IL-12, IFNα/β 
and IL-18 promote tumor elimination via STAT1 while IL-6, IL-22, indoleamine 2,3-
dioxygenase (IDO), IL-10 and TGFβ promote tumor escape via STAT3 [341, 349-
352].  
 
TNFα, as described in the previous chapter, is an important cytokine in IBD 
pathogenesis as treatment with anti-TNFα MAb shows to be successful in a majority 
of patients. Classically considered an anti-tumor agent, it has now also been indicated 
to promote tumor growth during chronic inflammation. TNFα can promote 
angiogenesis and induce expression of cyclooxygenase-2 (COX-2) an enzyme that by 
itself can promote angiogenesis as well [353]. Moreover, TNF-R deficient mice 
treated with AOM/DSS had reduced inflammation and tumor formation compared to 
wild type controls [354]. Furthermore, Rag-/- mice with H.hepaticus infection develop 
CAC, but this was suppressed by the neutralization of TNFα [355]. Neutralization of 
TNFα or TNF-R deficiency foremost leads to reduced inflammation in the above 
mentioned models, this gives rise to the question if the reduced tumor burden is a 
result of the direct effect of TNFα on tumor formation or if a less inflammatory 
environment is less pro-tumorigenic. 
 
Lower levels of Th1 and cytotoxic T cell related mRNA, such as T-bet, IFNγ and 
granzyme, were measured in tumors of CRC patients with early metastatic invasion 
compared to tumors from patients without such signs [356]. This and other studies 
indicated that increased Th1 and cytotoxic T cell infiltration in the tumors correlated 
with increased patient survival [356-358].  
 
Finally, removal of immune suppressive signals such as TGFβ results in increased 
intra-tumoral IFNγ, Th1 and cytotoxic CD8+ cells and reduced tumor burden [359]. 
Thus, tumor induced immune-evasion in human CRC and murine AOM/DSS induced 
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CAC is partly mediated by enhanced expression of immunosuppressive cytokines 
such as TGFβ and IL-10 within the tumor environment [313, 350]. Moreover IDO 
expression by antigen presenting cells has been implicated in the activation of Tregs 
in AOM/DSS induced CAC [351], and enhanced IDO expression in human CRC is 
correlated with worse prognosis [360]. 
 
Clinical and experimental data indicate that chronic intestinal inflammation in CAC 
act as a double-edged sword. Release of cytokines such as IL-6 and TNFα during 
chronic colitis can promote tumor growth and regulatory factors such as TGFβ can 
exacerbate this process. Thus, several factors that have been shown to be protective in 
IBD, such as IL-22, IL-10 and TGFβ have been indicated as important tumor 
promoting factors in CAC [347, 359, 361]. While for example Smad7 was shown to 
inhibit TGFβ-signaling in IBD patients which is thought to promote colitis [292], in 
another study the Smad7 expression in colonic tissue of IBD patients was correlated 
with less IBD related complications such as CAC [359]. Similar findings have been 
published for IL-22, IL-22 administration ameliorated experimental colitis and IL-22 
induced STAT3 signaling has been indicated to be important in mucosal wound 
healing in DSS induced colitis [362, 363]. While both in human CRC and 
experimental CAC IL-22 has been indicated to induce tumors in a STAT3 dependent 
manner [352, 364].  
 
Collectively data from these studies indicate that treatment of IBD and thereby 
reducing the inflammation in the intestine decreases the risk or CAC, but that patients 
with progressed disease and signs of dysplasia may require different treatment. It is 
currently unknown what impact most anti-inflammatory drugs and immune 
modulators have on IBD-related CAC, and if any of these drugs improve or dampen 
the immunosurveillance against dysplastic cells. Although clinical data indicate that 
5-aminosalicylate (5-ASA) may prevent CAC in UC patients [365]. 
 
5.4 Prognosis, surveillance and treatment of CRC/CAC  
Survival rate of CRC patients is about 50% in the first 5 years after diagnosis, with 
only 6 months average survival in untreated metastatic CRC [366]. To decrease the 
CAC cancer complications in IBD patients it is becoming common practice to 
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perform regular surveillance colonoscopy, however dysplasia is very difficult to 
distinguish from inflamed tissue, targeted biopsies are therefore recommended to be 
taken during surveillance [367]. Chemo-preventive agents can inhibit, delay or 
reverse colon carcinogenesis, 5-aminosalicylic acid (5-ASA) is an attractive candidate 
due to its indicated anti-carcinogenic effect, however clinical data is conflicting and 
needs further investigation [368]. Increasing evidence is indicates that non-steroid 
anti-inflammatory drugs (NSAIDs) can prevent premalignant polyps, CRC onset and 
recurrence [366]. In established CRC cytotoxic chemotherapy (e.g. 5-fluorouracil) in 
combination with biologicals (e.g. anti-endothelial growth factor (VEGF)) are 
frequently used [366].  
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Aims of the thesis 
 
The overall aim of this thesis work was to study the role of intestinal dendritic subsets 
in experimental models of T cell induced colitis and AOM/DSS induced CAC. 
 
More specifically: 
1. What is the role of IRF4 expressing cDC2s in T cell induced experimental colitis. 
2. What is the role of IRF8 expressing cDC1s in AOM/DSS induced CAC 
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Concluding remarks and future perspectives 
This thesis work summarizes current relevant knowledge on the intestinal immune 
system and the immunological alterations that contribute to pathologies of the 
intestinal tract. Our understanding of cDC lineages and their development and 
functionality has evolved significantly over the last decades. Their involvement in 
inflammatory bowel disorders and associated colorectal cancer however has not been 
studied in detail.  
 
Manuscript I describes that IRF4 expressing cDC2s have a role in the initial priming 
of colitogenic T cells and priming and maintenance of Th17 cells during colitis. 
Absence of IRF4 expressing cDC2s resulted in delayed onset of colitis. Absence of 
IRF4 expressing cDC2s interestingly also resulted in a reduction of colonic nTregs, 
but this did however not influence the total Tregs ability to prevent colitis. 
Manuscript II investigated the role of IRF8 expressing cDC1s in AOM/DSS induced 
experimental colorectal cancer. Consistent with studies under homeostatic conditions, 
absence of IRF8 expressing cDC1s resulted in a reduced Th1 response in the colon; 
this however did not affect the development of colorectal tumors in AOM/DSS 
induced colitis.  
 
As described in this thesis, inflammatory bowel disease is a complex and 
multifactorial disease. Some mutations such as IL-10R deficiency can directly lead to 
early onset colitis but in most patients it is a combination of genetics, dysbiosis or 
infection, intestinal barrier defects and sustained pro-inflammatory immunity [193, 
194, 369]. The fact that I could probably have written a thesis of about 100+ pages 
with all the knowledge gained over the last decades about the immunology of IBD 
from animal models and human disease illustrates the complexity of the disease. 
Recent advances in the mapping of the genetic basis of disease susceptibility however 
offer a tool for more focused research. There is however still a gap in what role 
mediators such as cDCs have in the onset of IBD. To follow up on manuscript I, the 
next step would be to investigate the role of IRF8 expressing cDC1s in experimental 
T cell mediated colitis. The question however is how efficient cDC1s are at priming 
CD4+ T cells, as they have been shown to be inferior to cDC2s at MHCII presentation 
[370]. cDC1s however are important producers of RA that imprints homing of T cells 
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to the small intestine LP and epithelium which might indicate that activated T cells in 
lymph nodes have reduced ability to home to the intestine [166], although this may 
not be applicable for homing to the colon as other chemokines have been implicated 
in homing of T cells to the colon. Moreover Th1 cell priming is impaired in the 
absence of cDC1s [166] and although Th1 cells are not the main driver of colitis, they 
may contribute to maintaining the pro-inflammatory environment. The significant 
infiltration of moDCs in the inflamed colon could indicate that once inflammation is 
established these moDCs have an important role in maintaining colitogenic T cells 
once colitis is established. CCR2 deficient mice however are still capable of inducing 
T cell mediated colitis despite impaired recruitment of monocytes to the intestine 
(unpublished results). Which may indicate that colitis establishment in T cell transfer 
colitis is dependent on cDC2 and possibly cDC1 priming of colitogenic T cells but 
that maintenance and progression of colitis occurs through the actions of moDCs or 
monocyte derived macrophages [142, 143].  
 
The result that IRF8 expressing cDC1s contributed to neither anti- nor pro-tumor 
immunity in the AOM/DSS model of CRC was to us surprising. Our observations that 
the tumor environment in AOM/DSS induced CRC harbored an altered immune cell 
composition compared to the non-tumor tissue however indicates that the tumor 
environment in this model creates an immune response that favors tumor growth. 
Moreover the observation that cDC1s were present in decreased proportions in tumor 
versus non-tumor tissue could indicate that the tumor environment inhibits cDC1s’ 
ability to prime an anti-tumor response. Future studies in this model could focus on 
the functionality of cDC1s in the tumor environment compared to the non-tumor 
environment (e.g. in vitro T cell stimulation assays with sorted cDC1s from tumors 
and non-tumor tissue). Moreover it would be of interest to investigate the roles of Th1 
cells and the separate roles of nTregs and pTregs in the AOM/DSS induced CRC 
model.  
 
Current treatments for IBD and CRC are not ideal as not all treatments are effective 
for all patient groups. Moreover, long-term effects of effective biologicals are not 
known and they are relatively costly. A better understanding of the immunological 
mechanisms and especially the mediator populations such as cDCs that potentially 
induce colitogenic responses is instrumental for the development of improved 
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treatments. The increased understanding of the underlying genetics and cross-talk of 
the immune system with the microbiota could assist the development of more 
personalized treatments. For example dendritic cell based vaccination could 
especially for the treatment of colorectal cancers form a more targeted treatment. DCs 
could be modulated in vitro with the ability to infiltrate tumors, alter the tumor 
induced immune-suppressive environment and induce CD8+ cytotoxic T cell 
responses. Although we are far from realizing this concept in IBD or CRC, for some 
cancers such as prostate cancer or metastatic melanoma DC based vaccinations have 
shown some success in clinical trials [371]. In IBD there is currently a major interest 
in the modulation of the microbiota in order to alter the immune response in the 
intestine of IBD patients, clinical trials have however been implemented with mixed 
results [305, 316, 317]. A better understanding of a "healthy" microbiota is needed 
and it might be of interest to investigate interactions between cDCs and the 
microbiota in more detail in order to find the "bugs" that can induce the desired 
immune response. For example clostridium species are potent inducers of pTreg 
responses [113], but the role of cDCs in the induction of these pTregs in response to 
clostridium species has not been addressed in detail. 
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